Jame Abraham, MD, on ER-Positive Breast Cancer: Expert Perspective on Initial Results of NRG Oncology/NSABP B-42
2016 San Antonio Breast Cancer Symposium
Jame Abraham, MD, of the Cleveland Clinic, gives his perspective on study results of extended adjuvant endocrine therapy in postmenopausal women with estrogen receptor–positive breast cancer who have completed previous adjuvant endocrine treatment (Abstract S1-05).
Ruth O’Regan, MD, of the University of Wisconsin, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss study findings on the prognostic associations of TILs in metastatic HER2-positive breast cancer (Abstract S1-04).
Joseph A. Sparano, MD, of the Montefiore Medical Center, discusses the tumor microenvironment of metastasis score and its association with early distant recurrence in HR-positive, HER2-negative early-stage breast cancer (Abstract S4-04).
To view a short film on capturing imaging inside breast cancer tumors, go to: https://www.youtube.com/watch?v=q_JDp-VePAs
Hyo Sook Han, MD, of Moffitt Cancer Center, discusses phase II study findings on the efficacy and tolerability of veliparib in combination with carboplatin and paclitaxel vs placebo in patients with BRCA1 or BRCA2 mutations and metastatic breast cancer (Abstract S2-05).
Diana M. Eccles, MD, of the University of Southampton, discusses findings from a study of sporadic and hereditary breast cancer and whether BRCA status affects outcome in young breast cancer patients (Abstract S2-03).
Anne Hudson Blaes, MD, of the University of Minnesota, discusses the association between aromatase inhibitors, endothelial function, and early heart disease (Abstract S5-07).